Pfizer Inc. (PFE)

NYQ – Real vaqt narxi. Valyuta: USD

25.87

+0.06 (0.23%)

Yopilishda: May 12, 2026, 4:02 PM EDT

25.76

-0.13 (-0.49%)

Bozor oldidan: May 13, 2026, 8:46 AM EDT

12.05.2026

Pfizer: Don't Pass On This Dirt-Cheap Buying Opportunity

Pfizer remains materially undervalued, trading at a 9.1x forward earnings multiple and offering a compelling 6.7% dividend yield. LOE headwinds are moderating, with management now expecting $14–15 billion in losses, below prior peak estimates, easing long-term revenue concerns. Execution on recently launched and acquired products is strong, with 22% operational growth and a robust pipeline, particularly in oncology and weight loss.

12.05.2026

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).

12.05.2026

Prediction: Pfizer Will Beat the Market Over the Next 5 Years

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own.

12.05.2026

3 Berkshire Stocks Under $30 and 2 Under $30 Greg Abel May Buy

Warren Buffett built Berkshire Hathaway by paying reasonable prices for durable cash flows, and three of his current bets still trade below $30 a share.

12.05.2026

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

12.05.2026

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant).

12.05.2026

Is Pfizer a Buy, Sell, or Hold in 2026?

Pfizer generates nearly $60 billion in annual revenue. The biggest risks facing Pfizer are upcoming patent cliffs, when drugs come off patent.

Videolar

05.05.2026

Neutral

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

05.05.2026

Positive

Pfizer CEO on AI-designed molecule, and race to use new tech

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
PFE	UBS	Neutral	undefined >> $25	January 7th 2026
PFE	Citigroup	Neutral	undefined >> $26	December 2nd 2025
PFE	Scotiabank	Sector Outperform	undefined >> $30	November 13th 2025
PFE	Cantor Fitzgerald	Neutral	undefined >> $24	April 22nd 2025
PFE	BofA Securities	Neutral	undefined >> $29	December 10th 2024
PFE	Wolfe Research	Underperform	undefined >> $25	November 15th 2024
PFE	Citigroup	Neutral	undefined >> $30	October 25th 2024
PFE	Bernstein	Market Perform	undefined >> $32	October 17th 2024

Press-relizlar

12.05.2026

Pfizer Inc. (PFE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pfizer Inc. (PFE)

Pfizer: Don't Pass On This Dirt-Cheap Buying Opportunity

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Prediction: Pfizer Will Beat the Market Over the Next 5 Years

3 Berkshire Stocks Under $30 and 2 Under $30 Greg Abel May Buy

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug